Skip to main content
NNVC
NYSE Life Sciences

NanoViricides Refreshes ATM Capacity to $8.4M Under S-3 Float Cap

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.16
Mkt Cap
$29.609M
52W Low
$0.85
52W High
$1.93
52W Position info
36% above low
Off High info
40% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

NNVC sits 36% above its 52-week low of $0.85.

Summary

NanoViricides reset its existing at-the-market program to allow up to $8.4M of additional share sales through D. Boral Capital, a large overhang for a company that just flagged going-concern doubt.


Key Events · Financing and Capital Events · NNVC

  • ATM Capacity Reset to $8.4M

    Amendment No. 3 to the July 17, 2026 sales agreement lets NanoViricides sell up to $8,376,444 of common stock through or to D. Boral Capital as agent or principal.

  • Float Cap Drives the Limit

    The ceiling is the S-3 General Instruction I.B.6 one-third-of-public-float limit: public float of $43,179,500 based on 25,550,000 non-affiliate shares at $1.69 as of the September 21, 2026 close.

  • Prior Sales Already Consumed Cap

    About $6,016,722 of shares were already sold under I.B.6 in the trailing 12-month period, so this amendment refreshes remaining headroom rather than opening a new facility.

  • Going-Concern Backdrop

    Filed one day after the 2026-11-16 10-Q, which reported a $5.7M quarterly loss, substantial doubt about ability to continue as a going concern, and the start of ATM share sales.


Analysis · NNVC · Life Sciences

This is Amendment No. 3 to a sales agreement first signed July 17, 2026 — not a new program. What changed is the size of the bucket: the company can now sell up to $8,376,444 of stock through D. Boral Capital, a limit set by the one-third-of-public-float rule because its $43.2M float is under $75M. Against a $29.6M market cap, that is a large overhang, and it lands one day after the 10-Q disclosed substantial doubt about continuing as a going concern and confirmed ATM sales had already started. Roughly $6.0M has already been sold under the cap in the trailing 12 months, so the practical read is continued drip-feed dilution to fund clinical spending rather than a one-time raise.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NNVC was trading at $1.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $0.85 to $1.93. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NNVC - Latest Insights

NNVC
Nov 16, 2026, 5:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $1.18 info
Change: -$0.050 (-4%) info
Market Cap: $29.609M info